- Home
- CTSO vs CRVO Comparison
CTSO vs CRVO Comparison
Compare CTSO & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- CRVO
- Stock Information
- Founded
- CTSO 1997
- CRVO 2001
- Country
- CTSO United States
- CRVO United States
- Employees
- CTSO N/A
- CRVO N/A
- Industry
- CTSO Medical/Dental Instruments
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- CRVO Health Care
- Exchange
- CTSO Nasdaq
- CRVO Nasdaq
- Market Cap
- CTSO 58.6M
- CRVO 67.4M
- IPO Year
- CTSO N/A
- CRVO N/A
- Fundamental
- Price
- CTSO $0.85
- CRVO $7.11
- Analyst Decision
- CTSO Buy
- CRVO Strong Buy
- Analyst Count
- CTSO 2
- CRVO 6
- Target Price
- CTSO $5.50
- CRVO $19.17
- AVG Volume (30 Days)
- CTSO 66.2K
- CRVO 111.2K
- Earning Date
- CTSO 11-06-2025
- CRVO 11-11-2025
- Dividend Yield
- CTSO N/A
- CRVO N/A
- EPS Growth
- CTSO N/A
- CRVO N/A
- EPS
- CTSO N/A
- CRVO N/A
- Revenue
- CTSO $36,107,520.00
- CRVO $7,776,968.00
- Revenue This Year
- CTSO $11.93
- CRVO N/A
- Revenue Next Year
- CTSO $21.22
- CRVO N/A
- P/E Ratio
- CTSO N/A
- CRVO N/A
- Revenue Growth
- CTSO 20.18
- CRVO N/A
- 52 Week Low
- CTSO $0.71
- CRVO $1.80
- 52 Week High
- CTSO $1.61
- CRVO $16.94
- Technical
- Relative Strength Index (RSI)
- CTSO 39.19
- CRVO 37.80
- Support Level
- CTSO $0.80
- CRVO $6.76
- Resistance Level
- CTSO $0.86
- CRVO $7.30
- Average True Range (ATR)
- CTSO 0.04
- CRVO 0.52
- MACD
- CTSO -0.01
- CRVO -0.09
- Stochastic Oscillator
- CTSO 24.74
- CRVO 12.07
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.